Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

75 results about "Missense mutation" patented technology

In genetics, a missense mutation is a point mutation in which a single nucleotide change results in a codon that codes for a different amino acid. It is a type of nonsynonymous substitution.

A multi-modal classifier system for missense mutation pathogenicity prediction

The present invention relates to a computer-implemented multi-module classifier method and system for providing a pathogenicity classification score of a variant of a protein of interest. The classifier comprises a sequence module based on a protein language model (PLM); a structure module based on a graph neural network (GNN); a property module; and a unified head module based on a machine learning model. The invention further relates to methods for preparing, training, and implementing the multi-module classifier system.
Owner:SHEBA IMPACT LTD

Missense mutation function effect prediction model construction method and prediction method

ActiveCN120126557AEnsemble learningBiostatisticsMolecular phenotypeGenetics
The invention discloses a missense mutation function effect prediction model construction method and a prediction method, and relates to the technical field of biological information. According to the method, on the basis of pathogenic and benign missense mutation data, various molecular phenotypic characteristics are enriched and annotated through statistical indexes, and a machine learning model for mutation function effect prediction is constructed. The model fuses feature information of a plurality of molecular levels, comprises comprehensive evaluation indexes of a residual base level, a mutation level and a protein level, and is trained and optimized based on a random forest algorithm. The method not only can accurately predict pathogenic mutation, but also shows excellent performance in recognition of cancer-driven missense mutation, has good generalization ability and biological interpretability, and can provide solid technical support for pathogenicity and carcinogenicity recognition of missense mutation and molecular mechanism research of missense mutation.
Owner:SUZHOU UNIV

Application of NPFFR2 gene SNP (Single Nucleotide Polymorphism) site in judging hysteritis resistance of dairy cow

The invention discloses application of an NPFFR2 gene SNP site in judgment of dairy cow hysteritis resistance, and belongs to the technical field of livestock and poultry molecular biology, the SNP site is rs110326785, and the site generates Ggt; the metritis resistance of a dairy cow individual with the genotype of GG at the site is obviously higher than that of dairy cow individuals with the genotypes of GA and AA. The mutation of the SNP site rs110326785 is missense mutation, so that glutamic acid at the 406th site of an amino acid sequence coded by NPFFR2 mutates into lysine, when the genotype of the site is GG, the dairy cow metritis resistance is the highest, and the SNP site can be used for screening and identifying dairy cows with high metritis resistance, so that dairy cow individuals with high metritis resistance are selected for cattle herd optimization and auxiliary breeding.
Owner:INST OF ANIMAL SCI & VETERINARY MEDICINE SHANDONG ACADEMY OF AGRI SCI +1

RNAi TARGETING KIF1A MISSENSE MUTATIONS FOR TREATMENT OF KIF1A ASSOCIATED NEUROLOGICAL DISORDER

RNAi involving siRNA, shRNA, or antisense oligonucleotides (ASO) are provided that reduce expression of toxic KIF1A alleles thereby reducing production of mutant KIF1A for treatment of KAND. Also provided are RNA-targeting oligonucleotides that reduce expression of toxic KIF1A alleles herein incorporate sequences that target common benign single nucleotide polymorphisms (SNPs) which are present in cis with one or more causative KIF1A mutations.
Owner:OVID THERAPEUTICS INC

Molecular marker and breeding method for breeding eggshell color of Liuyang black-bone chicken

The invention provides a molecular marker and a breeding method for breeding the eggshell color of a Liuyang black-bone chicken, and particularly relates to the field of molecular breeding. The invention finds that a missense mutation (C21R) in the ABCG2 gene is associated with the eggshell color variation of the Liuyang black-bone chicken brown shell egg, so that the ABCG2 gene can be used for molecular-assisted breeding of the eggshell color of the Liuyang black-bone chicken brown shell egg. The C21R is a missense mutation occurring on the 21th cysteine of ABCG2 protein, and the C21R is a missense mutation occurring on the 21th cysteine of ABCG2 protein; c, causing. According to the breeding method, the genotype of the C21R locus of an individual to be detected is detected through PCR (Polymerase Chain Reaction) amplification and Sanger sequencing. According to a detection result, CC type individuals are selected and reserved for breeding, and a new black-bone chicken strain capable of laying deep brown shell eggs can be bred in an auxiliary mode; tT type individuals are selected and reserved for breeding, and the new black-bone chicken strain capable of producing light brown shell eggs can be bred in an auxiliary mode. The method provided by the invention solves the problem of inconsistent egg color caused by gene mutation of the existing Liuyang black-bone chickens, can greatly shorten the breeding time of a new black-bone chicken strain for laying eggs with specific brown shell color, and reduces the breeding cost.
Owner:NORTHWEST A & F UNIV +2

Missense mutation function classification method and system based on multiple omics characteristics

The invention relates to the technical field of biological gene mutation prediction, in particular to a multi-omics feature-based missense mutation function classification method and system. The classification method comprises the following steps: S1, collecting a multi-omics comprehensive feature set related to missense mutation; s2, constructing a heterogeneous graph; s3, learning a meta-path-based weight of each node in the heterogeneous graph; s4, calculating weights of different meta-paths by using attention of a semantic level; s5, performing weighted summation on the node weight and the meta-path weight to obtain final embedding representation of each node; s6, training to obtain a multi-omics feature-based missense mutation function classification model; and S7, outputting a prediction score based on the multi-omics feature missense mutation function classification model, and dividing missense mutation according to the prediction score. According to the method, the heterogeneous graph is constructed by utilizing multiple omics characteristics, and the relationship between biological entities is explicitly modeled, so that GOF and LOF mutations are distinguished more accurately.
Owner:CENT SOUTH UNIV

Novel mRNA tumor vaccine for treating mouse liver cancer

The invention relates to the technical field of tumor vaccines, and provides a novel mRNA (messenger Ribonucleic Acid) tumor vaccine for treating mouse liver cancer, which is prepared by the following steps: S1, specific neoantigen prediction: carrying out bioinformatics analysis on a next-generation sequencing database of tumor patients in the hospital, and selecting tumor specific neoantigens through the following steps; s11, low-quality readings are removed through a filtering step; s12, detecting single nucleotide variation by using a Mutect method and a VarScan method; s13, annotating missense mutation by using ANNOVAR software; in-vivo and in-vitro experiments prove that the vaccine has a remarkable anti-tumor effect, is designed and synthesized aiming at a newly screened new antigen mutation sequence and has high specificity and pertinence, and experimental results show that the vaccine can remarkably improve immune response of specific CTLs cells, induce T cell response of new antigen specificity, and has a good anti-tumor effect in a tumor-bearing mouse model. The vaccine has a remarkable inhibiting effect on tumor growth, and the problems in the prior art are solved through the technical scheme.
Owner:CHANGZHOU TUMOR HOSPITAL (CHANGZHOU FOURTH PEOPLES HOSPITAL)

Genetically modified obese mouse model

Mouse models of obesity associated with human MC4R missense mutations are provided. Human mutations introduced with CRISPR / Cas9 into the mouse MC4R gene lead to an severely obese mouse phenotype in mice with a heterozygous genotype.
Owner:CONGRUENCE THERAPEUTICS INC

TREM for use in correction of missense mutations

The present invention generally relates to tRNA-based effector molecules for use in inserting missense mutations into the open reading frame (ORF) of a gene, e.g., for the treatment of repetitive sequence amplification diseases.
Owner:FLAGSHIP PIONEERING INNOVATIONS VI LLC

A method for directed evolution of escherichia coli antibiotic resistant strains based on cytidine deaminase

PendingCN122629099AEscherichia coliKanamycin
This invention discloses a method for directed evolution of antibiotic-resistant Escherichia coli strains based on cytidine deaminase, belonging to the field of microbial directed evolution and genetic engineering technology. This method uses E. coli as the host, introducing a recombinant plasmid expressing an optimized double-stranded cytidine deaminase mutant. Utilizing the low toxicity and high mutagenicity of this mutant, continuous passage evolution is carried out under gradient concentrations of aminoglycoside antibiotics (kanamycin and streptomycin). Combined with whole-genome sequencing, molecular docking, and reverse genetics verification, the A145T missense mutation in the wcaE gene is identified as the core functional site. This invention overcomes the shortcomings of traditional spontaneous and chemical mutagenesis, which suffer from low efficiency and significant strain damage. The mutation type is controllable, the evolutionary cycle is short, and the obtained engineered strains can tolerate up to 300 mg / L kanamycin while exhibiting streptomycin cross-resistance, and the genetic stability of the tolerance trait is strong. This method is simple, highly reproducible, and suitable for industrial breeding of stress-resistant E. coli, and can be widely applied in antibiotic fermentation, industrial microbial culture, and other scenarios.
Owner:TIANJIN UNIV

Molecular marker related to egg shell color and application thereof

The invention relates to the technical field of agricultural breeding, and discloses a molecular marker related to egg shell color and application of the molecular marker, the SNP molecular marker corresponds to the 18378867 site from the 5'terminal on a chicken reference genome GRCg6a 6 # chromosome published in an Ensembl gene browser database, and the base of the site is C / T and is missense mutation on an ABCG2 gene. The SNP molecular marker is related to the egg shell color, is a new molecular marker, can accelerate the breeding progress of the character by detecting the genotype of the locus of a chicken individual to be determined and performing early selection on the chicken with the dominant genotype, and has great application value and economic benefit.
Owner:INSTITUTE OF ANIMAL SCIENCES OF CHINESE ACADEMY OF AGRICULTURAL SCIENCES

Engineered tRNA and methods of use thereof

In general, the present disclosure relates to tRNAs encoding an amino acid but covalently linked to a different amino acid. The tRNA can correct missense mutations during protein synthesis by providing different amino acids. Such tRNAs can be used to correct pathogenic missense mutations.
Owner:UNIVERSITY OF CHICAGO

Rnai targeting KIF1a missense mutations for treatment of KIF1a associated neurological disorder

PCT designated stage expiredWO2024254242A2Polymorphism usesDNA/RNA fragmentationNucleotideMedicine
RNAi involving siRNA, shRNA, or antisense oligonucleotides (ASO) are provided that reduce expression of toxic KIF1A alleles thereby reducing production of mutant KIF1A for treatment of KAND. Also provided are RNA-targeting oligonucleotides that reduce expression of toxic KIF1A alleles herein incorporate sequences that target common benign single nucleotide polymorphisms (SNPs) which are present in cis with one or more causative KIF1A mutations.
Owner:OVID THERAPEUTICS INC

SNP (Single Nucleotide Polymorphism) molecular marker related to pig body length character and application

PendingCN121023033AMicrobiological testing/measurementFood processingX chromosomeDomestic pig
The invention discloses an SNP (Single Nucleotide Polymorphism) molecular marker related to a pig body length character and application, and belongs to the technical field of biology. The SNP molecular marker is located on a pig X chromosome, and an SNP site is located at the 467th basic group of a pig BHLHB9 gene coding region (A in ATG in the coding region is 1); the basic group of the SNP site is C / T missense mutation. The SNP molecular marker related to the pig body length character is disclosed for the first time, is used for distinguishing individuals with medium and short body lengths and individuals with long body lengths, is suitable for domestic pig breeds and foreign pig breeds, and is wide in pig breed application range. The method for detecting the genotype of the SNP molecular marker disclosed by the invention can be used for quickly and effectively predicting the body length of a pig in an early stage at low cost, has a wide application prospect in the aspect of improvement of a pig variety strain, and can obtain an excellent economic value.
Owner:CHINA AGRI UNIV

Lasofoxifene combined treatment of ER + breast cancer progressing after treatment of CDK4 / 6 inhibitor

The present invention provides a method of slowing the progression of ER + breast cancer in a patient comprising administering to the patient an effective amount of lasofoxifene or a pharmaceutically acceptable salt thereof and an effective amount of a CDK4 / 6 inhibitor (CDK4 / 6i) wherein breast cancer: (i) is estrogen receptor positive (ER +); (ii) having at least one function-acquired missense mutation within the ligand binding domain (LBD) of the estrogen receptor 1 (ESR1) gene; and (iii) have progressed and / or have oncogenic mutations in genes other than ESR1 during previous treatment with a CDK4 / 6 inhibitor.
Owner:THERMEX PHARM +1

Methods of treating fabry disease in patients having mutation in gla gene

To provide: methods of treating a patient diagnosed with or suspected of having Fabry disease; and methods of enhancing α-GalA in a patient diagnosed with or suspected of having Fabry disease.SOLUTION: There is provided a method comprising administering to a patient a therapeutically effective dose of a pharmacological chaperone for α-GalA, wherein the patient has a missense mutation in a nucleic acid sequence encoding α-GalA.SELECTED DRAWING: None
Owner:AMICUS THERAPEUTICS INC

ENGINEERED tRNA AND METHODS OF USE

PendingUS20260248838A1DiseaseMissense mutation
In general, the current disclosure relates to the tRNAs that encode for one amino acid but are covalently linked to a different amino acid. The tRNAs can correct missense mutations by providing a different amino acid during protein synthesis. Such tRNAs can be used to correct disease-causing missense mutations.
Owner:UNIVERSITY OF CHICAGO

Novel human-derived distal bile duct cancer cell line with TP53 missense mutation and application of novel human-derived distal bile duct cancer cell line

The invention provides a novel human distal bile duct cancer cell line with TP53 missense mutation and application, the novel human distal bile duct cancer cell line CBC3T-3 is established, the cell line is preserved in the China Center for Type Culture Collection (the preservation number is CCTCC NO: C202555), the uniqueness and stability of the cell line are proved through STR typing and karyotype analysis, and the TP53 missense mutation novel human distal bile duct cancer cell line has the advantages that the TP53 missense mutation novel human distal bile duct cancer cell line CBC3T-3 can be used for preparing the TP53 missense mutation novel human distal bile duct cancer cell line CBC3T-3; and a plurality of driver gene mutations including TP53 missense mutation are carried. The CBC3T-3 has strong proliferation, invasion and migration capabilities, has high tumor formation rate in immunodeficient mice, is resistant to cis-platinum and sensitive to paclitaxel and gemcitabine, and provides an experimental basis for selection of clinical chemotherapy regimens. According to the model, the TP53 missense mutation type distal bile duct cancer in-vitro model is successfully established, and a key experimental platform is provided for deeply researching the drug resistance mechanism of the TP53 missense mutation type distal bile duct cancer and developing an individualized treatment strategy aiming at the subtype of the TP53 missense mutation type distal bile duct cancer.
Owner:THE FIRST HOSPITAL OF LANZHOU UNIV

Lasofoxifene treatment of aromatase-resistant er+ cancer

PendingUS20260207550A1Aromatase inhibitorEstrogen receptor gene
The disclosure provides methods for treating estrogen receptor positive (ER+) cancer in a patient who has progressed on an aromatase inhibitor. Of particular interest are ER+ cancers that do not harbor a gain of function missense mutation within the ligand binding domain (LBD) of the Estrogen Receptor 1 (ESR1) gene. The provided methods involve the administration of an effective amount of lasofoxifene, a pharmaceutically acceptable salt, prodrug or functional derivative thereof.
Owner:SERMONIX PHARMACEUTICALS INC

A molecular marker related to the color of chicken eggshell and application thereof

ActiveCN121874361BBiotechnologyAnimal science
The application relates to the technical field of agricultural breeding, and discloses a molecular marker related to eggshell color and application thereof. The SNP molecular marker corresponds to a site of 18378867 from a 5' end on a chromosome 6 of a chicken reference genome GRCg6a published in an Ensembl genome browser database, the base of the site is C / T, and the site is a missense mutation on an ABCG2 gene. The SNP molecular marker related to the eggshell color is a new molecular marker. By detecting the genotype of the site of a chicken individual to be determined, early selection is carried out on the chicken with an advantageous genotype, the breeding progress of the trait can be accelerated, and the application has great application value and economic benefits.
Owner:INSTITUTE OF ANIMAL SCIENCES OF CHINESE ACADEMY OF AGRICULTURAL SCIENCES

Gene signature for prediction of treatment response in cancers with microsatellite instability or mismatch repair deficiency

PCT designated stageWO2026030822A1Organic active ingredientsOrganic chemistryRecQ HelicasesARID1A
A gene signature for evaluating likely sensitivity of a cancer cell to treatment with inhibitors of Werner syndrome RecQ helicase (WRN) is provided. For cancer cells that have microsatellite instability (MSI) and / or mismatch repair deficiency (dMMR), sensitivity to treatment with a WRN inhibitor is likely if the cancer cell has a loss of function mutation in at least two of KMT2D, ARID1A or RAD50, or if the cancer cell has a loss of function mutation in ARID1A only, without loss of function mutations in KMT2D and RAD50. Cancer cells that are MSI and / or dMMR in which both ARID1A and at least one of KMT2D and RAD50 are wild type or have only missense mutations are unlikely to be sensitive to treatment with WRN inhibitors.
Owner:PROVINCIAL HEALTH SERVICES AUTHORITY +1

Composition for detecting RHO gene polymorphism

The invention belongs to the field of molecular biological detection, and particularly relates to a composition and a method for joint detection and distinguishing of six missense mutation sites (c.50C > T, c.68C > A, c.151G > C, c.310G > A, c.403C > T and c.647T > A) of an RHO gene, and application of the composition and the method for joint detection and distinguishing of the six missense mutation sites (c.50C > T, c.68C > A, c.151G > C, c.310G > A, c.403C > T and c.647T > A) of the RHO gene. The multiplex PCR technology and the nucleic acid mass spectrum are adopted, and the six missense mutation sites c.50C > T, c.68C > A, c.151G > C, c.310G > A, c.403C > T and c.647T > A of the RHO gene can be simultaneously detected in one tube of reaction liquid. Nucleic acid extraction and single-tube PCR amplification only need to be carried out once for one sample, the needed sample size is low, sensitivity and accuracy are high, the detection limit is low, and early intervention of retinitis pigmentosa can be timely and effectively assisted.
Owner:SANSURE BIOTECH INC

A molecular marker for the EGR1 gene SNP associated with goat fertility and its application

PendingCN123108166AAnimal scienceMedicine
This invention relates to the field of goat breeding technology, and more particularly to a molecular marker for a SNP in the EGR1 gene related to goat fertility and its application. This SNP marker is located at the g.1487C>A site in the EGR1 gene and is a missense mutation (c.518C>A, p.Thr173Asn). Detecting the genotype at this site can identify goat fertility traits: wild-type homozygous individuals with the CC genotype have significantly higher litter numbers than mutant heterozygous individuals with the CA genotype, and shorter litter intervals. This invention also provides primer pairs specifically for amplifying this SNP, a kit containing these primer pairs, and corresponding identification and breeding methods. This invention enables early selection of goat reproductive traits, shortens the breeding cycle, and improves breeding efficiency.
Owner:SOUTHWEST UNIV

Establishment method and application of antitumor drug cell screening model based on TBR1 site-directed mutants

The invention provides an anti-tumor drug cell screening model establishment method based on a TBR1 site-directed mutant and application, and belongs to the technical field of biological medicine. By analyzing data of patients with medullary blastoma (MB) in children hospital of Nanjing Medical University and clinical patients with MB in EGA database, it is found that the proportion of Group 4 subtype MB is the highest, and TBR1 mutation specifically exists in Group 4 subtype MB; a mutation spectrum of TBR1 in Group 4 subtype MB clinical patient data is analyzed, a result shows that mutation is missense mutation, mutation sites are all concentrated in a T-box structural domain of TBR1, and a TBR1-G275 site is high-frequency mutation; the method comprises the following steps: designing a site 275 of a pegRNA targeted TBR1 T-box region by using a CRISPR-Cas9-based PE (Polyethylene) technology, carrying out site-directed mutagenesis on TBR1 in a Group 4 subtype D283 cell line on a genome level, and successfully constructing the Group 4 subtype MB cell model with TBR1-G275C mutation by using a method of drug screening, monoclonal culture and final sequencing verification.
Owner:NANJING MEDICAL UNIV

Method and system for predicting influence of missense mutation on clinical efficacy based on deep learning

The application provides a method and system for predicting the influence of missense mutations on clinical drug efficacy based on deep learning, comprising the following steps: S1, obtaining and preprocessing drug and mutant protein sequence data sets; S2, normalizing drug input data; S3, normalizing mutant protein sequence input data; S4, building a deep learning model according to the normalized data, and outputting a prediction classification. The application can predict the influence of mutations on clinical drug efficacy only using the structure attributes of drugs and mutant protein sequences. Since the application uses a relatively small feature dimension, it supports high-throughput mutation drug efficacy prediction with low computational overhead. The application can use a deep learning method to predict the influence of mutations on clinical drug use with high precision while maintaining interpretability, and the input features do not include clinical drug information and crystal structure determination experimental information.
Owner:SHANGHAI JIAOTONG UNIV

RNAi TARGETING HNRNPH2 MISSENSE MUTATIONS FOR TREATMENT OF BAIN SYNDROME

RNAi involving siRNA or shRNA is provided that reduces expression of toxic HNRNPH2 alleles containing one or more R206W, R206Q and P209L missense mutations thereby reducing production of mutant HNRNPH2 for treatment of Bain Syndrome. RNAi involving siRNA or shRNA is provided that reduces expression of wild-type HNRNPH2 thereby reducing production of HNRNPH2 for treatment of Bain Syndrome.
Owner:OVID THERAPEUTICS INC

Application of ALPK2 gene missense mutation marker in breeding of pigs with dominant production traits

The invention discloses application of an ALPK2 gene missense mutation marker in breeding of pigs with dominant production traits, and belongs to the technical field of molecular genetics and livestock breeding. By detecting ALPK2 gene mutation and screening individuals carrying mutation rs327271406 as a GG genotype, individuals with excellent growth traits (fast growth and high meat production performance) of European pig breeds can be rapidly screened out, the breeding period is shortened, the meat production efficiency of pig herds is improved, the breeding cost is reduced, the method is used for early screening of pig breeds with fast growth and high meat yield, high-quality pig herd breeding is accelerated, and the economic benefit is increased. The method evaluates the pig muscle development potential, guides molecular marker assisted breeding, and is especially used for commercialized lean type pig production.
Owner:AGSINO GENSOURCES CO LTD

RNAi targeting KIF1A missense mutations for treatment of KIF1A-associated neurological disorders

Provided are RNAi involving siRNA, shRNA or antisense oligonucleotide (ASO) that reduce the expression of toxic KIF1A alleles, thereby reducing the production of mutant KIF1A, for use in the treatment of KAND. Also provided are RNA targeting oligonucleotides that reduce the expression of toxic KIF1A alleles herein incorporate sequences that target common benign single nucleotide polymorphisms (SNPs) that are cis present with one or more pathogenic KIF1A mutations.
Owner:OVID THERAPEUTICS INC